DE60229430D1 - (20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen - Google Patents

(20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen

Info

Publication number
DE60229430D1
DE60229430D1 DE60229430T DE60229430T DE60229430D1 DE 60229430 D1 DE60229430 D1 DE 60229430D1 DE 60229430 T DE60229430 T DE 60229430T DE 60229430 T DE60229430 T DE 60229430T DE 60229430 D1 DE60229430 D1 DE 60229430D1
Authority
DE
Germany
Prior art keywords
skin
compound
bishomopregnacalciferol
methylene
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229430T
Other languages
English (en)
Inventor
Hector F Deluca
Lori A Plum
Margaret Clagett-Dame
James B Thoden
Hazel M Holden
Sumithra Gowlugari
Pawel Grzywacz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/078,204 external-priority patent/US6627622B2/en
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Application granted granted Critical
Publication of DE60229430D1 publication Critical patent/DE60229430D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE60229430T 2001-12-13 2002-12-12 (20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen Expired - Lifetime DE60229430D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34113801P 2001-12-13 2001-12-13
US10/078,204 US6627622B2 (en) 2002-02-18 2002-02-18 (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
PCT/US2002/039715 WO2003051828A2 (en) 2001-12-13 2002-12-12 (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses

Publications (1)

Publication Number Publication Date
DE60229430D1 true DE60229430D1 (de) 2008-11-27

Family

ID=26760229

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229430T Expired - Lifetime DE60229430D1 (de) 2001-12-13 2002-12-12 (20s)-1 alpha-hydroxy-2-methylen-19-nor-bishomopregnacalciferol und ihre verwendungen

Country Status (17)

Country Link
EP (1) EP1453798B1 (de)
JP (1) JP4149928B2 (de)
KR (1) KR100631457B1 (de)
CN (1) CN1308303C (de)
AT (1) ATE411283T1 (de)
AU (1) AU2002359680B2 (de)
CA (1) CA2468833C (de)
CY (1) CY1108686T1 (de)
DE (1) DE60229430D1 (de)
DK (1) DK1453798T3 (de)
ES (1) ES2315426T3 (de)
HK (1) HK1077804A1 (de)
MX (1) MXPA04005652A (de)
NZ (1) NZ533424A (de)
PT (1) PT1453798E (de)
SI (1) SI1453798T1 (de)
WO (1) WO2003051828A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7704980B2 (en) * 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US8404667B2 (en) * 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
DE602005026694D1 (de) * 2004-11-22 2011-04-14 Wisconsin Alumni Res Found 2-methylen-19,21-dinor-1alpha-hydroxy-bishomopregnacalciferol
US8222235B2 (en) 2004-11-22 2012-07-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20R)-1α-hydroxy-bishomopregnacalciferol
AU2005309791A1 (en) * 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2-methylene-19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and its uses
JP2008542201A (ja) * 2005-05-03 2008-11-27 ウイスコンシン アラムニ リサーチ ファンデーション １９，２６，２７−トリノル−１α，２５−ジヒドロキシビタミンＤ３化合物
JP2010505739A (ja) * 2006-04-06 2010-02-25 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−１α，２５−ジヒドロキシ−１９，２１−ジノルビタミンＤ３類縁体およびその使用
WO2008035207A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
WO2008035206A2 (en) * 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1 alpha-hydroxy-18,19,21-trinorvitamin d3 analogs and uses thereof
WO2008089093A2 (en) * 2007-01-12 2008-07-24 Quatrx Pharmaceuticals Company Efficient processes for preparing steroids and vitamin d derivatives with the unnatural configuration at c20 (20 alpha-methyl) from pregnenolone
WO2009111695A1 (en) * 2008-03-06 2009-09-11 Wisconsin Alumni Research Foundation Methods of increasing epidermal skin thickness by topical administration of a 19-nor containing vitamin d compound
US8993547B2 (en) * 2011-06-14 2015-03-31 Wisconsin Alumni Research Foundation 3-desoxy-2-methylene-19-nor-vitamin D analogs and their uses
US20130178449A1 (en) * 2011-07-18 2013-07-11 Wisconsin Alumni Research Foundation 2-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs
CA2851275C (en) * 2011-10-21 2020-07-14 Wisconsin Alumni Research Foundation 2-methylene-vitamin d analogs and their uses
JP6114292B2 (ja) * 2011-10-21 2017-04-12 ウイスコンシン アラムニ リサーチ ファンデーション ２−メチレン−ビタミンｄ類似体およびそれらの使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3680740D1 (de) * 1985-04-23 1991-09-12 Wisconsin Alumni Res Found Die differenzierung maligner zellen bewirkende seco-sterol-verbindungen.
JPH05238937A (ja) * 1992-03-09 1993-09-17 Wisconsin Alumni Res Found 細胞分化誘発薬剤
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
JP4022144B2 (ja) * 2000-09-08 2007-12-12 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １アルファ−ヒドロキシ−２−メチレン−１９−ノル−ホモプレグナカルシフェロール及びその療法的適用

Also Published As

Publication number Publication date
AU2002359680B2 (en) 2007-10-18
CA2468833C (en) 2009-09-08
MXPA04005652A (es) 2005-03-23
CY1108686T1 (el) 2014-04-09
WO2003051828A3 (en) 2003-09-12
PT1453798E (pt) 2009-01-23
HK1077804A1 (en) 2006-02-24
NZ533424A (en) 2006-08-31
WO2003051828A2 (en) 2003-06-26
DK1453798T3 (da) 2009-02-16
AU2002359680A1 (en) 2003-06-30
CN1308303C (zh) 2007-04-04
ATE411283T1 (de) 2008-10-15
CN1620431A (zh) 2005-05-25
KR20040063949A (ko) 2004-07-14
SI1453798T1 (sl) 2009-04-30
EP1453798A2 (de) 2004-09-08
KR100631457B1 (ko) 2006-10-11
CA2468833A1 (en) 2003-06-26
JP4149928B2 (ja) 2008-09-17
JP2005513066A (ja) 2005-05-12
ES2315426T3 (es) 2009-04-01
EP1453798B1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
HK1077804A1 (en) (20S)-1Alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
DE60215225D1 (de) Alpha-hydroxy-2-methylen-10-nor-pregnacalciferol und seine anwendungen
DE60105035D1 (de) 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol und seine therapeutische verwendungen
ATE415164T1 (de) (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung
WO2006057884A3 (en) 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES
WO2006057899A3 (en) 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses
ATE467614T1 (de) 2-methylen-19,26,27-trinor-(20s)-1-alpha- hydroxyvitamin d3 and dessen verwendungen
WO2006057901A3 (en) 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES
ATE472528T1 (de) 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen
ATE552239T1 (de) 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga
WO2006057902A3 (en) 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses
WO2009086439A3 (en) 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition